Related Experiment Video
Updated: May 26, 2026
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
Published on: September 30, 2025
Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of
1Division of Metabolism, Endocrinology and Nutrition, Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, WA 98109, USA. bhshao@u.washington.edu
Insights
Myeloperoxidase (MPO) and reactive carbonyls like malondialdehyde (MDA) can damage high-density lipoprotein (HDL), reducing its heart-protective cholesterol-efflux function. These modifications are found in cardiovascular disease patients and atherosclerotic lesions.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Oxidative Stress
Background:
- High-density lipoprotein (HDL) possesses cardioprotective properties, but the mechanisms causing HDL dysfunction are not fully understood.
- Myeloperoxidase (MPO) and reactive carbonyls are implicated in cardiovascular and diabetic vascular diseases.
- HDL dysfunction may contribute to the progression of atherosclerosis.
Purpose of the Study:
- To investigate the roles of myeloperoxidase (MPO) and reactive carbonyls in generating dysfunctional HDL.
- To identify specific modifications of apolipoprotein A-I (apoA-I) by MPO and reactive carbonyls.
- To correlate these modifications with HDL function and their presence in human cardiovascular disease.
Main Methods:
- Mass spectrometric analysis to detect MPO products (3-chlorotyrosine, 3-nitrotyrosine) and reactive carbonyl adducts (MDA, acrolein) in HDL.
- Biochemical assays to assess the impact of MPO and reactive carbonyl modification on apoA-I's ability to promote cholesterol efflux via the ABCA1 pathway.
- Immunochemical analysis to detect MDA-protein adducts and acrolein adducts in HDL from atherosclerotic lesions.
Main Results:
- Levels of MPO-specific tyrosine modifications and MDA-protein adducts were elevated in HDL from cardiovascular disease patients and atherosclerotic lesions.
- MPO oxidation of apoA-I diminished its cholesterol efflux capacity by impairing the ABCA1 pathway.
- Modification of apoA-I by malondialdehyde (MDA) or acrolein also impaired cholesterol efflux, with adducts found at specific lysine residues.
Conclusions:
- Myeloperoxidase (MPO) and reactive carbonyls, such as malondialdehyde (MDA), can generate dysfunctional HDL in humans.
- Oxidative modification of apoA-I by MPO and reactive carbonyls impairs HDL's ability to facilitate cholesterol efflux.
- These findings highlight potential mechanisms for HDL dysfunction in cardiovascular disease pathogenesis.
Abstract:
The mechanisms that deprive HDL of its cardioprotective properties are poorly understood. One potential pathway involves oxidative damage of HDL proteins by myeloperoxidase (MPO) a heme enzyme secreted by human artery wall macrophages. Mass spectrometric analysis demonstrated that levels of 3-chlorotyrosine and 3-nitrotyrosine - two characteristic products of MPO - are elevated in HDL isolated from patients with established cardiovascular disease. When apolipoprotein A-I (apoA-I), the major HDL protein, is oxidized by MPO, its ability to promote cellular cholesterol efflux by the membrane-associated ATP-binding cassette transporter A1 (ABCA1) pathway is diminished. Biochemical studies revealed that oxidation of specific tyrosine and methionine residues in apoA-I contributes to this loss of ABCA1 activity. Another potential mechanism for generating dysfunctional HDL involves covalent modification of apoA-I by reactive carbonyls, which have been implicated in atherogenesis and diabetic vascular disease. Indeed, modification of apoA-I by malondialdehyde (MDA) or acrolein also markedly impaired the lipoprotein's ability to promote cellular cholesterol efflux by the ABCA1 pathway. Tandem mass spectrometric analyses revealed that these reactive carbonyls target specific Lys residues in the C-terminus of apoA-I. Importantly, immunochemical analyses showed that levels of MDA-protein adducts are elevated in HDL isolated from human atherosclerotic lesions. Also, apoA-I co-localized with acrolein adducts in such lesions. Thus, lipid peroxidation products might specifically modify HDL in vivo. Our observations support the hypotheses that MPO and reactive carbonyls might generate dysfunctional HDL in humans. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010).
Related Concept Videos
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:30Atherosclerosis I: Introduction
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease II: Pathophysiology
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...